Patient characteristics associated with chemotherapy-induced peripheral neuropathy severity in a phase II clinical trial: A retrospective analysis Journal Article
| Authors: | Zhi, W. I.; Dreyfus, N.; Lessing, A.; Galantino, M.; Piulson, L.; Kot, K. L.; Li, S.; Bao, T. |
| Article Title: | Patient characteristics associated with chemotherapy-induced peripheral neuropathy severity in a phase II clinical trial: A retrospective analysis |
| Abstract: | Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) can lead to chemotherapy dose reduction, delay, and discontinuation, and has limited effective prevention strategies. Our study aimed to identify patient characteristics associated with CIPN severity during weekly paclitaxel chemotherapy in people with early-stage breast cancer. Methods: We retrospectively collected baseline data including participants' age, gender, race, body mass index (BMI), hemoglobin (regular and A1C), thyroid stimulating hormone, Vitamins (B6, B12, and D), anxiety, and depression up to 4 months prior to their first paclitaxel treatment. We also collected CIPN severity by Common Terminology Criteria for Adverse Events (CTCAE) after chemotherapy, chemotherapy relative dose density (RDI), disease recurrence, and mortality rate at the time of the analysis. Logistic regression was used for statistical analysis. Results: We extracted 105 participants' baseline characteristics from electronic medical records. Baseline BMI was associated with CIPN severity (Odds Ratio [OR] 1.08; 95% CI, 1.01-1.16, P=.024). No significant correlations were observed in other covariates. At median follow-up (61 months), there were 12 (9.5%) breast cancer recurrences and six (5.7%) breast cancer-related deaths. Higher chemotherapy RDI was associated with improved disease-free survival (DFS, OR 1.025; 95% CI, 1.00-1.05; P=.028). Conclusions and Relevance: Baseline BMI may be a risk factor for CIPN and suboptimal chemotherapy delivery due to CIPN may negatively impact disease-free survival in patients with breast cancer. Further study is warranted to identify mitigating lifestyle factors to reduce incidences of CIPN during breast cancer treatment. © 2023 The Author(s). Published by Oxford University Press. |
| Keywords: | retrospective studies; clinical trial; antineoplastic agents; paclitaxel; antineoplastic agent; phase 2 clinical trial; neoplasm recurrence, local; breast cancer; peripheral neuropathy; breast neoplasms; retrospective study; body mass index; tumor recurrence; breast tumor; peripheral nervous system diseases; humans; human; female |
| Journal Title: | The Oncologist |
| Volume: | 28 |
| Issue: | 7 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-07-01 |
| Start Page: | 604 |
| End Page: | 608 |
| Language: | English |
| DOI: | 10.1093/oncolo/oyad062 |
| PUBMED: | 36972359 |
| PROVIDER: | scopus |
| PMCID: | PMC10322124 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Wangqing Zhi -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work